Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CAP-100 |
| Synonyms | |
| Therapy Description |
CAP-100 is a monoclonal antibody that targets CCR7, which potentially induces antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells and decreases tumor cell migration (PMID: 34297159). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CAP-100 | CAP 100|CAP100 | CAP-100 is a monoclonal antibody that targets CCR7, which potentially induces antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells and decreases tumor cell migration (PMID: 34297159). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04704323 | Phase I | CAP-100 | CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia | Recruiting | USA | ESP | 0 |